Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced management participation in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The company is focused on developing treatments for complex rare diseases, particularly its lead compound CTI-1601, which is undergoing a Phase 1 clinical program for Friedreich's ataxia. Larimar aims to leverage its intracellular delivery platform to create new fusion proteins for additional rare diseases.

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33^rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is Larimar Therapeutics planning at the Piper Sandler Conference?

Larimar Therapeutics will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021.

What is Larimar's lead compound and its purpose?

Larimar's lead compound, CTI-1601, is being evaluated as a potential treatment for Friedreich's ataxia.

What type of company is Larimar Therapeutics?

Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for complex rare diseases.

What diseases does Larimar Therapeutics target?

Larimar focuses on rare diseases characterized by deficiencies in intracellular bioactive compounds.